Horizon Therapeutics (Horizon Therapeutics) Total Assets : $9,299 Mil (As of Jun. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Horizon Therapeutics Total Assets?

Horizon Therapeutics's Total Assets for the quarter that ended in Jun. 2023 was $9,299 Mil.

During the past 12 months, Horizon Therapeutics's average Total Assets Growth Rate was -2.30% per year. During the past 3 years, the average Total Assets Growth Rate was 26.20% per year. During the past 5 years, the average Total Assets Growth Rate was 19.10% per year. During the past 10 years, the average Total Assets Growth Rate was 45.90% per year.

During the past 13 years, Horizon Therapeutics's highest 3-Year average Total Assets Growth Rate was 354.00%. The lowest was -4.00%. And the median was 45.10%.

Total Assets is connected with ROA %. Horizon Therapeutics's annualized ROA % for the quarter that ended in Jun. 2023 was 5.56%. Total Assets is also linked to Revenue through Asset Turnover. Horizon Therapeutics's Asset Turnover for the quarter that ended in Jun. 2023 was 0.10.

Horizon Therapeutics Total Assets Historical Data

The historical data trend for Horizon Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Horizon Therapeutics Total Assets Chart

Horizon Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Assets

Get a 7-Day Free Trial

3,941.96

4,436.03

6,072.62

8,677.73

9,114.62

Horizon Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Total Assets	Get a 7-Day Free Trial															8,853.47	9,027.86	9,114.62	8,993.45	9,298.74

Horizon Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Horizon Therapeutics's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (A: Dec. 2022 )	+	Total Liabilities (A: Dec. 2022 )
	=	5072.174	+	4042.442
	=	9,115

Horizon Therapeutics's Total Assets for the quarter that ended in Jun. 2023 is calculated as

Total Assets	=	Total Equity (Q: Jun. 2023 )	+	Total Liabilities (Q: Jun. 2023 )
	=	5310.959	+	3987.782
	=	9,299

Horizon Therapeutics (NAS:HZNP) Total Assets Explanation

Total Assets is connected with ROA %.

Horizon Therapeutics's annualized ROA % for the quarter that ended in Jun. 2023 is

ROA %	=	Net Income (Q: Jun. 2023 )	/	( (Total Assets (Q: Mar. 2023 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	508.284	/	( (8993.45	+	9298.741)	/ 2 )
	=	508.284	/	9146.0955
	=	5.56 %

Note: The Net Income data used here is four times the quarterly (Jun. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Horizon Therapeutics's Asset Turnover for the quarter that ended in Jun. 2023 is

	Asset Turnover
=	Revenue (Q: Jun. 2023 )	/	( (Total Assets (Q: Mar. 2023 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
=	944.959	/	( (8993.45	+	9298.741)	/ 2 )
=	944.959	/	9146.0955
=	0.10

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Horizon Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Horizon Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Horizon Therapeutics (Horizon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Horizon Therapeutics PLC (NAS:HZNP) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

70 St. Stephen’s Green, Dublin, IRL, D02 E2X4

Website

https://www.horizontherapeutics.com

Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.

Executives

Andy Pasternak	officer: EVP and Chief Business Officer	C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 D04 C5Y6
Aaron Cox	officer: EVP, Chief Financial Officer	C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Jeffrey W Sherman	officer: EVP & Chief Medical Officer	C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Patrick Mcilvenny	officer: Chief Accounting Officer	C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Sean M. Clayton	officer: EVP, General Counsel	C/O HORIZON THERAPEUTICS PLC, 70 SAINT STEPHENS GREEN, DUBLIN L2 D02 E2X4
Thompson Elizabeth H.z.	officer: EVP, Research & Development	C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Timothy P Walbert	director, officer: President, Chairman and CEO	1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Jacopo Leonardi	officer: Chief Commercial Officer	C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Paul W. Hoelscher	officer: EVP Finance	1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015
Michael A. Desjardin	officer: EVP, Technical Operations	C/O JAZZ PHARMACEUTICALS, INC., 3180 PORTER DRIVE, PALO ALTO CA 94304
Miles W Mchugh	officer: Principal Accounting Officer	C/O ACCRETIVE HEALTH, INC., 401 N. MICHIGAN AVE, SUITE 2700, CHICAGO IL 60611
Barry Moze	officer: EVP, Corporate Dev't.	C/O HORIZON PHARMA, INC., 520 EAST COOK ROAD, SUITE 520, DEERFIELD IL 60015
Brian K Beeler	officer: EVP, General Counsel	C/O HORIZON PHARMA PLC, 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60015
Michael G Grey	director	C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
William F Daniel	director	TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000